ReviewAging2013
Immunostimulatory activity of lifespan-extending agents.
Review in Aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06249620 (A Randomized Controlled Trial of Oral Suplementation With AM3, Hesperidin and Spermidine on Immunity Response and Biological Age in Healthy Volunteers.), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial of Oral Suplementation With AM3, Hesperidin and Spermidine on Immunity Response and Biological Age in Healthy Volunteers.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Targeting immunosenescence and inflammaging: advancing longevity research.Experimental & molecular medicine · 2025Review
- Screening the medicine for malaria venture's Pandemic Response Box to identify novel inhibitors of Candida albicans and Candida auris biofilm formation.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2023Article
- Therapeutic Antiaging Strategies.Biomedicines · 2022Review
- Antiaging agents: safe interventions to slow aging and healthy life span extension.Natural products and bioprospecting · 2022Review
- From causes of aging to death from COVID-19.Aging · 2020Review
- Review
- Rapamycin for longevity: opinion article.Aging · 2019Article
- Gerosuppression by pan-mTOR inhibitors.Aging · 2016Article
- Identification ofAging · 2016Article
- Article
- Article
- Rejuvenating immunity: "anti-aging drug today" eight years later.Oncotarget · 2015Article
- Review
- Questioning the preclinical paradigm: natural, extreme biology as an alternative discovery platform.Aging · 2014Review
- HDAC inhibitors and immunotherapy; a double edged sword?Oncotarget · 2014Review
- Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.Cancer biology & therapy · 2014Article
- Latest progress in tyrosine kinase inhibitors.Oncotarget · 2014Article
- Comparison of rapamycin schedules in mice on high-fat diet.Cell cycle (Georgetown, Tex.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the past two decades, several interventions have been shown to increase the healthy lifespan of model organisms as evolutionarily distant from each other as yeast, worms, flies and mammals. These anti-aging maneuvers include (but are not limited to) cycles of caloric restriction, physical exercise as well as the administration of multiple, chemically unrelated agents, such as resveratrol, spermidine and various rapamycin-like compounds collectively known as rapalogs. Most, if not all, lifespan-extending agents promote macroautophagy (hereafter referred to as autophagy), an evolutionarily old mechanism that contributes to the maintenance of intracellular homeostasis and plays a critical role in the adaptive response of cells to stress. In line with this notion, the activation of autophagy appears to mediate significant anti-ageing effects in several organisms, including mice. Here, we focus on rapalogs to discuss the possibility that part of the beneficial activity of lifespan-extending agents stems from their ability to exert immunostimulatory effects. Accumulating evidence indicates indeed that the immune system can recognize and eliminate not only cells that are prone to undergo malignant transformation, but also senescent cells, thus playing a significant role in the control of organismal aging. In addition, it has recently become clear that rapamycin and other rapalogs, which for a long time have been viewed (and used in the clinic) as pure immunosuppressants, can mediate robust immunostimulatory functions, at least in some circumstances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.